Skip to main content
SpringerPlus

Table 3 mT-staging validation for the indication of RT treatment

From: Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy

 

DRE/TRUS n (%)

mpMRI n (%)

p value

Prostatectomy piece n (%)

T-category

T1–T2a

84 (93.7)

24 (26.7)

< 0.001

23 (25.6)

T2b–T2c

6 (6.7)

54 (60.0)

57 (63.3)

T3–T4

0

12 (13.3)

10 (11.1)

Risk group

Low-risk

43 (47.8)

13 (14.4)

< 0.001

10 (11.1)

Intermediate-risk

37 (41.1)

59 (65.6)

65 (72.2)

High-risk

10 (11.1)

18 (20.0)

15 (16.7)

Global reliability for T-category

8 (8.8)

64 (71.1)

< 0.001

 

Risk group change due to pathological analysis

37 (41.1)

15 (16.7)

< 0.001

 

Changes related to RT parameters (HT, Doses, CTV)

Initial criteria

45 (50.0)

16 (17.8)

< 0.001

 

MSKCC criteria

59 (65.6)

18 (20.0)

 
  1. For patients whose final treatment consisted of RP (n = 90), the cT-and mT-category were compared to the pathologic tumour stage (pT-category), which allowed us to validate DRE/TRUS and mpMRI results. Furthermore, the analysis and comparisons related to RT treatment decisions were done for DRE/TRUS vs. mpMRI
  2. RT radiotherapy, HT hormonal therapy, CTV clinical target volume
Back to article page